Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab

被引:16
作者
Karimi, Amirali [1 ]
Alilou, Sanam [1 ]
Mirzaei, Hamid Reza [2 ]
机构
[1] Univ Tehran Med Sci, Sch Med, Tehran, Iran
[2] Univ Tehran Med Sci, Sch Med, Dept Med Immunol, Tehran, Iran
关键词
CTLA4; Anti-CTLA4; antibody; ipilimumab; adverse events; cancer immunotherapy;
D O I
10.3389/fonc.2021.624780
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ipilimumab, a monoclonal anti-CTLA4 antibody, paved the path for promising treatments, particularly in advanced forms of numerous cancers like melanoma. By blockading CTLA-4, ipilimumab can abolish the higher binding affinity of B7 for CTLA-4, setting CD28 free to act unlimited. This blockade can result in an amplified antitumor immune response, and thereby, boosting more effective tumor regression. However, this blockage can lead to diminished self-tolerance and yielding autoimmune complications. The current review aims to describe adverse events (AEs) following the administration of ipilimumab in different cancers as every benefit comes at a cost. We will also discuss AEs in two different categories, melanoma and non-melanoma, owing to the possible shining promises in treating non-melanoma cancers. As the melanoma settings are more studied than other cancers, it might even help predict the patterns related to the other types of cancers. This similarity also might help physicians to predict adverse events and correctly manage them in non-melanoma cancers using the extensive findings reported in the more-studied melanoma settings. Recognizing the adverse events is vital since most of the adverse events could be reverted while carefully implementing guidelines. Finally, we will also describe the observed effectiveness of ipilimumab in non-melanoma cancers. This effectiveness reveals the importance of understanding the profile of adverse events in this group, even though some have not received FDA approval yet. Further clinical trials and careful systematic reviews may be required to decipher the hidden aspects of therapies with ipilimumab and its related AEs.
引用
收藏
页数:10
相关论文
共 58 条
[1]   Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma [J].
Albarel, Frederique ;
Gaudy, Caroline ;
Castinetti, Frederic ;
Carre, Tiphaine ;
Morange, Isabelle ;
Conte-Devolx, Bernard ;
Grob, Jean-Jacrues ;
Brue, Thierry .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2015, 172 (02) :195-204
[2]   THE YIN AND YANG OF T-CELL COSTIMULATION [J].
ALLISON, JP ;
KRUMMEL, MF .
SCIENCE, 1995, 270 (5238) :932-933
[3]   Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma [J].
Ansell, Stephen M. ;
Hurvitz, Sara A. ;
Koenig, Patricia A. ;
LaPlant, Betsy R. ;
Kabat, Brian F. ;
Fernando, Donna ;
Habermann, Thomas M. ;
Inwards, David J. ;
Verma, Meena ;
Yamada, Reiko ;
Erlichman, Charles ;
Lowy, Israel ;
Timmerman, John M. .
CLINICAL CANCER RESEARCH, 2009, 15 (20) :6446-6453
[4]   Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial [J].
Antonia, Scott J. ;
Lopez-Martin, Jose A. ;
Bendell, Johanna ;
Ott, Patrick A. ;
Taylor, Matthew ;
Eder, Joseph Paul ;
Jaeger, Dirk ;
Pietanza, M. Catherine ;
Le, Dung T. ;
de Braud, Filippo ;
Morse, Michael A. ;
Ascierto, Paolo A. ;
Horn, Leora ;
Amin, Asim ;
Pillai, Rathi N. ;
Evans, Jeffry ;
Chau, Ian ;
Bono, Petri ;
Atmaca, Akin ;
Sharma, Padmanee ;
Harbison, Christopher T. ;
Lin, Chen-Sheng ;
Christensen, Olaf ;
Calvo, Emiliano .
LANCET ONCOLOGY, 2016, 17 (07) :883-895
[5]   Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC [J].
Arriola, Edurne ;
Wheater, Matthew ;
Galea, Ian ;
Cross, Nadia ;
Maishman, Tom ;
Hamid, Debbie ;
Stanton, Louise ;
Cave, Judith ;
Geldart, Tom ;
Mulatero, Clive ;
Potter, Vannessa ;
Danson, Sarah ;
Woll, Pennella J. ;
Griffiths, Richard ;
Nolan, Luke ;
Ottensmeier, Christian .
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (09) :1511-1521
[6]   Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial [J].
Ascierto, Paolo A. ;
Del Vecchio, Michele ;
Robert, Caroline ;
Mackiewicz, Andrzej ;
Chiarion-Sileni, Vanna ;
Arance, Ana ;
Lebbe, Celeste ;
Bastholt, Lars ;
Hamid, Omid ;
Rutkowski, Piotr ;
McNeil, Catriona ;
Garbe, Claus ;
Loquai, Carmen ;
Dreno, Brigitte ;
Thomas, Luc ;
Grob, Jean-Jacques ;
Liszkay, Gabriella ;
Nyakas, Marta ;
Gutzmer, Ralf ;
Pikiel, Joanna ;
Grange, Florent ;
Hoeller, Christoph ;
Ferraresi, Virginia ;
Smylie, Michael ;
Schadendorf, Dirk ;
Mortier, Laurent ;
Svane, Inge Marie ;
Hennicken, Delphine ;
Qureshi, Anila ;
Maio, Michele .
LANCET ONCOLOGY, 2017, 18 (05) :611-622
[7]   Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer [J].
Bang, Yung-Jue ;
Cho, Jae Yong ;
Kim, Yeul Hong ;
Kim, Jin Won ;
Di Bartolomeo, Maria ;
Ajani, Jaffer A. ;
Yamaguchi, Kensei ;
Balogh, Agnes ;
Sanchez, Teresa ;
Moehler, Markus .
CLINICAL CANCER RESEARCH, 2017, 23 (19) :5671-5678
[8]   CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation [J].
Bashey, Asad ;
Medina, Bridget ;
Corringham, Sue ;
Pasek, Mildred ;
Carrier, Ewa ;
Vrooman, Linda ;
Lowy, Israel ;
Solomon, Scott R. ;
Morris, Lawrence E. ;
Holland, H. Kent ;
Mason, James R. ;
Alyea, Edwin P. ;
Soiffer, Robert J. ;
Ball, Edward D. .
BLOOD, 2009, 113 (07) :1581-1588
[9]   Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer [J].
Beer, Tomasz M. ;
Kwon, Eugene D. ;
Drake, Charles G. ;
Fizazi, Karim ;
Logothetis, Christopher ;
Gravis, Gwenaelle ;
Ganju, Vinod ;
Polikoff, Jonathan ;
Saad, Fred ;
Humanski, Piotr ;
Piulats, Josep M. ;
Gonzalez Mella, Pablo ;
Ng, Siobhan S. ;
Jaeger, Dirk ;
Parnis, Francis X. ;
Franke, Fabio A. ;
Puente, Javier ;
Carvajal, Roman ;
Sengelov, Lisa ;
McHenry, M. Brent ;
Varma, Arvind ;
van den Eertwegh, Alfonsus J. ;
Gerritsen, Winald .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (01) :40-+
[10]   Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial [J].
Coens, Corneel ;
Suciu, Stefan ;
Chiarion-Sileni, Vanna ;
Grob, Jean-Jacques ;
Dummer, Reinhard ;
Wolchok, Jedd D. ;
Schmidt, Henrik ;
Hamid, Omid ;
Robert, Caroline ;
Ascierto, Paolo A. ;
Richards, Jon M. ;
Lebbe, Celeste ;
Ferraresi, Virginia ;
Smylie, Michael ;
Weber, Jeffrey S. ;
Maio, Michele ;
Bottomley, Andrew ;
Kotapati, Srividya ;
de Pril, Veerle ;
Testori, Alessandro ;
Eggermont, Alexander M. M. .
LANCET ONCOLOGY, 2017, 18 (03) :393-403